“Visual acuity outcomes after cataract surgery in patients with age-related macular degeneration: age-related eye disease study report no. 27.”, Ophthalmology, vol. 116, no. 11, pp. 2093-100, 2009.
, “Visual Acuity Outcomes after Cataract Surgery in Patients with Age-Related Macular Degeneration; AREDS Report No. 27”, Ophthalmology, vol. 116, pp. 2093-100, 2009.
, “Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19.”, Ophthalmol Retina, vol. 4, no. 1, pp. 3-12, 2020.
, “Visual Acuity Loss Associated With Advanced AMD Fundus Lesions and With the Simplified AREDS AMD Severity Scale”, in Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, FL, 2007.
, “Visual acuity as an outcome measure in clinical trials of retinal diseases.”, Ophthalmology, vol. 114, no. 10, pp. 1804-9, 2007.
, “Visual Acuity as an Outcome Measure in Clinical Trials of Retinal Diseases”, Ophthalmology, vol. 114, pp. 1804-1809, 2007.
, “Visual acuity after cataract surgery in patients with age-related macular degeneration: age-related eye disease study 2 report number 5.”, Ophthalmology, vol. 121, no. 6, pp. 1229-36, 2014.
, “Visual Acuity After Cataract Surgery in Patients with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 5”, Ophthalmology, vol. 121, pp. 1229-1236, 2014.
, “Viral kinetics in untreated versus treated acute HIV infection in prospective cohort studies in Thailand.”, J Int AIDS Soc, vol. 20, no. 1, p. 21652, 2017.
, “Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates.”, J Infect Dis, vol. 201, no. 5, pp. 720-9, 2010.
, “Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of Human Immunodeficiency Virus-1 Vaccine Candidates”, J Infect Dis, vol. 201, pp. 720-729, 2010.
, “Vinorelbine Tartrate [in the treatment of breast cancer],”, American Hospital Formulary Service Drug Information, pp. 802-04, 1996.
, , “Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).”, Pediatr Transplant, vol. 1, no. 1, pp. 37-42, 1997.
, “Varicella in the first year after renal transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study.”, Pediatr Transpl., vol. 1, pp. 37-42, 1997.
, “Variation of community consultation and public disclosure for a pediatric multi-centered "Exception from Informed Consent" trial.”, Clin Trials, vol. 12, no. 1, pp. 67-76, 2015.
, “Variation of Community Consultation and Public Disclosure for a Pediatric Multi-Centered "Exception from Informed Consent" Trial”, Clin Trials, vol. 12, pp. 67-76, 2015.
, , “Variables affecting estimated glomerular filtration rate after renal transplantation in children: a NAPRTCS data analysis.”, Pediatr Transplant, vol. 14, no. 2, pp. 288-94, 2010.
, “Variables Affecting Estimated Glomerular Filtration Rate after Renal Transplantation in Children: A NAPRTCS Data Analysis”, Pediatr Transplant, vol. 14, pp. 288-294, 2010.
, , “Validation of the TAPS-1: A Four-Item Screening Tool to Identify Unhealthy Substance Use in Primary Care.”, J Gen Intern Med, vol. 32, no. 9, pp. 990-996, 2017.
, “Validation of the NIDA-modified ASSIST as a Screening Tool for Prenatal Drug Use in an Urban Setting in the United States.”, J Addict Med, 2020.
, “Validation of a Genomic Classifier that Predicts Metastatic Disease Progression in Men with High Risk Pathological Features Post-Prostatectomy”, in American Urological Association Annual Meeting, San Diego, CA, 2013.
, “Validation of a Genomic Classifier that Predicts Metastatic Disease Progression in Men with High-Risk Pathologic Features Postprostatectomy”, in American Society of Clinical Oncology, Genitourinary Cancers Symposium, Orlando, FL, 2013.
,